Pathogenetic treatment of patients with hypertension depending on the level of sympathоadrenal system activity
DOI:
https://doi.org/10.34287/MMT.1(48).2021.2Abstract
Purpose of the study. Recently, new opportunities to optimize clinical efficacy and tolerability of treatment of patients with essential hypertension appeared. Determination of the indicators of increased activity of the sympathetic nervous system (SNS) in practice could contribute to differentiated treatment of patients with hypertension. Comparative estimation of influence of complex treatment with bisoprolol or amlodipine on the SNS activity parameters in patients with arterial hypertension (AH) of II stage.
Materials and methods. 121 patients (men and women) with documented II stage AH were examined clinically. Concentrations of adrenaline, noradrenaline, dopamine and DOPA in urine were evaluated by spectrochromatography, endotheliumdependent vasodilation was studied using complex rheographic ReoCom Professional (HAI-Medicom, Ukraine). Patients were divided into 2 groups: if concentration of noradrenalin in urine exceeds healthy subjects levels more than on 20% – patients were added to basic treatment (enalapril, atorvastatin, aspirin) bisoprolol, if concentration of noradrenalin in urine exceeds healthy subjects levels less than on 20% – we added amlodipine. Statistic analysis was done on Apache OpenOffice (version 4.1) and PSPP (version 0.7.9).
Results. The study showed that after treatment there was significant decrease of adrenalin, noradrenalin in 1st group . Increase of DOPA levels was higher in 1st group (Δ% = +46,5 [30,0; 55,4]% vs Δ% = +8,8 [–2,1 ; 16,0]%, (p < 0,05).). Trends in daily urinary excretion of adrenaline (–44,8%) and norepinephrine (–33,7%) showed the impact of effective Δ-blocker on the activity of pressor systems. DOPA excretion was increased significantly in both groups which can indirectly indicate hemodynamic load reduction in hypertensive patients. When choosing the individual antihypertensive treatment in patients with arterial hypertension, if excretion of noradrenalin is increased it is rationally to add adjuvant therapy with β-blockers.
Conclusion. The results of our research can be applied into the practice of general practitioner as recommendations for individual selection of antihypertensive treatment depending on the activity of sympathetic nervous system.
References
Arterialna gipertenziya. Onovlena ta adaptovana klinichna nastanova, zasnovana na dokazah. Asotsiatsiya kardiologiv Ukrayini. K, 2012, 139 p.
Williams B. et al. 2018 ESC.ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European heart journal. 2018; 39 (33): 3021–104.
Grisk O. Hypertension and the sympathetic nervous system – recent developments in research and treatment Dtsch. Med. Wochenschr. 2009; 134 (45): 2289–93.
Zateyschikov DA, Dankovtseva EN. β-adrenoblokatoryi v kardiologii: metoprolol. Spravochnik poliklinicheskogo vracha. 2007; 9: 14–18.
Fujiwara H et al. Effect of low–dose landiolol, an ultrashort–acting beta–blocker, on postoperative atrial fibrillation after CABG surgery. Gen Thorac Cardiovasc Surg. – 2009. – Vol. 57 (3). – P. 132–137.
Heusser K, Tank J, Engeli S et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010. 55 (3): 619–26.
Lishnevskaya V Yu. Vyibor betaadrenoblokatora trudnomu patsientu. Liki Ukrayini. 2013; 1: 54–65.
Runihina N K, Tkacheva O N. Amlodipin: vozmozhnosti snizheniya riska oslozhneniy arterialnoy gipertenzii. Sistemnyie gipertenzii. 2009; 4:15–19.
Costanzo P, Perrone-Filardi P, Petretta M. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175 634 patients. Hypertens. 2009; 27: 1136–51.
Galanova AS, Osiya AO, Shilov AM. Patofiziologicheskie aspektyi blokatorov kaltsievyih kanalov v lechenii serdechno-sosudistyih zabolevaniy. RMZh. 2007; 20: 1494–97.
Serkova VK, Kuzminova NV, Alshantti Ya. SH i dr. Vliyanie amlodipina na protsessyi remodelirovaniya serdtsa i sosudov u bolnyih gipertonicheskoy boleznyu. Biomedical and Biosocial Anthropology. 2008; 10: 214–17.
Koh KK, Han SH, Ahn JY. Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. Int J Cardiol.2009; 133 (1): 23–31.
Gilyarevskiy SR, Golshmid MV, Kuzmina IM. Rol digidropiridinovyih antagonistov kaltsiya pri lechenii bolnyih s arterialnoy gipertoniey i ozhireniem v sootvetstvii s sovremennyimi klinicheskimi rekomendatsiyami. Rossiyskiy kardiologicheskiy zhurnal. – 2014; 4: 113–19.
Zanchetti A. Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve. Eur Heart J. 2010; 31: 2837–2840.
Martsevich S. Yu. Antagonistyi kaltsiya iz gruppyi digidropiridinov: dannyie dokazatelnoy meditsinyi i prakticheskie rekomendatsii po ispolzovaniyu. Ratsionalnaya farmakoterapiya v kardiologii. 2007; 1: 55–59.
Curran MP. Amlodipine. Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. Drugs. 2010; 70 (2): 191–213.
